Emerald Acquisition’s Regenxbio RGNX Stock Holding History

Emerald Acquisition’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$150K	Buy	+10,695	New	+$118K	﹤0.01%	2749

Other funds holding RGNX

BCPEM

Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Emerald Acquisition's RGNX Position: Q3 2016 in Review

Emerald Acquisition opened a new position in Regenxbio (RGNX) in Q3 2016: 10,695 shares worth $150K. The stake represents ﹤0.01% of the portfolio and ranks #2749 among its holdings.

71 funds tracked by Wall St. Rank hold RGNX as of Q3 2016.

Emerald Acquisition held 10,695 shares of Regenxbio worth $150K as of Q3 2016.
Regenxbio was a new Emerald Acquisition position in Q3 2016.
Regenxbio made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2749 holding.
71 funds tracked by Wall St. Rank held Regenxbio as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.